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Abstract
Objective—Elevated inflammatory cytokine levels have been implicated in the pathogenesis of 
non3 healing chronic venous insufficiency (CVI) ulcers. The goal of this study was to determine 
the protein levels of a wide range of inflammatory cytokines in untreated CVI ulcer tissue before 
and after 4 weeks of high strength compression therapy. These levels were compared to cytokines 
present in healthy tissue.
Methods—Thirty limbs with untreated CVI and leg ulceration received therapy for 4 weeks with 
sustained high compression bandaging at an ambulatory wound center. Biopsies were obtained 
from healthy and ulcerated tissue before and after therapy. A multiplexed protein assay was used 
to measure multiple cytokines in a single sample. Patients were designated as rapid or delayed 
healers based on ulcer surface area change.
Results—The majority of pro-inflammatory cytokine protein levels were elevated in ulcer tissue 
compared to healthy tissue, and compression therapy significantly reduced these cytokines. TGF-
β1 was up-regulated in ulcer tissue following compression therapy. Rapid healing ulcers had 
significantly higher levels of IL-1α, IL-1β, IFN-γ, IL-12p40 and GM-CSF before compression 
therapy, and IL-1 Ra after therapy. IFN-γ levels significantly decreased following therapy in the 
rapidly healing patients.
Conclusion—CVI ulcer healing is associated with a pro-inflammatory environment prior to 
treatment that reflects metabolically active peri-wound tissue that has the potential to heal. 
Treatment with compression therapy results in healing that is coupled with reduced pro-
inflammatory cytokine levels and higher levels of the anti-inflammatory cytokine IL-1 Ra.
Clinical Relevance—This data suggests that cytokines may provide targets in which topical 
therapeutic inhibition or promotion at appropriate time points in the healing process may provide 
novel therapeutic approaches to the healing of CVI ulcers.
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INTRODUCTION
In the United States, chronic venous insufficiency (CVI) is the most common etiology of 
chronic non-healing lower extremity ulcers, estimated to be responsible for over 75% of 
cases. Though rarely a cause of limb amputation, these chronic wounds result in significant 
morbidity, pain, and are estimated to cause more than 2 million lost work days per year.1 
These ulcerations negatively impact a person’s quality of life, especially if delayed healing 
is experienced.2 The majority of patients with leg ulcers and associated venous insufficiency 
will experience progressive healing when treated with sustained limb compression of 30 
mmHg or greater3–5, but healing typically requires 3–6 months of treatment or longer. Also, 
a subset of patients experiences delayed or no healing despite receiving medical 
treatment.6–8
Previous studies have identified up-regulation of various pro-inflammatory cytokines in 
fluid collected from venous leg ulcers. It has been hypothesized that chronic venous 
hypertension results in an inflammatory state that is responsible for poor ulcer healing.9, 10 
Although compression therapy results in healing of most venous leg ulcers, the mechanism 
responsible for this effect is not well defined.
Historically, cytokine proteins levels have been quantified separately. Luminex multiplex 
technology allows for the simultaneous evaluation of multiple cytokines in a single sample. 
Microspheres, which are dyed beads coated with a specific capture antibody, are added to a 
sample. The cytokines of interest are captured by the microspheres. Fluorescent tagged 
detection antibodies are added, and samples are fed through a flow cytometer. A dual laser 
excites the internal dyes that identify each microsphere particle (cytokine of interest) and 
reads the quantity of the fluorescent detection antibodies, which are in direct proportion to 
the bound cytokine. This technology gives the advantages of higher throughput, smaller 
sample volume, and improved sensitivity. Other researchers have used multiplexed 
immunoassays to measure cytokines in various bodily fluids.11–13
The main study goal was to quantify both pro- and anti-inflammatory levels in healthy and 
CVI ulcer tissue before and after sustained compression therapy using a multiplexed assay. 
The second goal was to identify inflammatory markers related to ulcer healing status. We 
hypothesized that pro-inflammatory levels would be elevated in venous ulcers with 
associated low levels of anti-inflammatory cytokine levels compared to healthy tissue. 
Following compression therapy, ulcer tissue was expected to demonstrate cytokine levels 
similar to the healthy tissue pattern. Delayed healing ulcers would theoretically have 
continued elevation of pro-inflammatory levels.
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Enrolled patients were 18 years of age or greater with onset of lower extremity ulceration 
and edema (CEAP class 6, primary or secondary etiology) within 6 months of study 
participation per history, physical exam and referring physician documentation. Only 
patients that had not received previous compression therapy were included. Abnormal 
venous function and CEAP criteria were examined using duplex ultrasonography and air 
plethysmography. Patients that did not meet criteria for venous insufficiency on both studies 
were excluded. Duplex ultrasonography was performed with patients in a standing position 
using an automatic inflation/deflation cuff system (Hokanson E20 Rapid Cuff Inflator and 
AG101 Cuff Inflator Air Source, Issaquah, WA), and CVI was defined as the presence of 
reflux in the deep or superficial veins of > 0.5 sec.14 An abnormal venous filling index as 
assessed by air plethysmography was > 2ml/sec.15
Exclusion criteria included an Ankle to Brachial Index (ABI) of less than 0.7, congenital 
venous insufficiency, previous treatment with any form of high strength compression 
bandaging, active systemic infection, severe immunocompromised state, dressing allergy, 
use of an investigational drug, history of vasculitis or poor medical compliance. This 
protocol was approved by the University of North Carolina at Chapel Hill’s Institutional 
Review Board and Independent Ethics Committee. Informed consent was obtained from all 
patients prior to study enrollment.
Wounds were debrided, and a 3-layer or 4-layer compression bandage system (Profore lite 
or Profore, Smith and Nephew, Hull, United Kingdom) was applied over a polyurethane 
foam primary dressing. Dressings and compression bandages were changed weekly. 
Wounds were photographed at the initial and subsequent visits.
Planimetry, which used tracings of the ulcer perimeter, was performed weekly using the 
Visitrak Digital system (Smith & Nephew) to determine wound surface area changes.16 
Previous studies of venous ulcer healing with compression therapy have reported that the 
percentage change in wound area between baseline and 3 to 4 weeks of treatment is 
predictive of eventual healing. Kantor and Margolis found that improvement at 4 weeks was 
predictive of eventual healing and Phillips reported that a reduced wound size of 40% at 3 
weeks of treatment was predictive of complete healing at 12 weeks of treatment.17–18 Based 
on these studies, we chose to treat study patients with weekly compression bandaging for 4 
weeks at which time healing progress and repeat tissue analysis was performed. Patients 
who had at least a 40% reduction in ulcer surface area at 4 weeks were designated as rapid 
healers and those who healed less than 40% were designated as delayed healers.
Tissue Sample Collection
Prior to biopsy 1% lidocaine was injected for local anesthesia. Full thickness punch biopsies 
6mm in diameter and 2–3 mm in depth were obtained from the wound tissue adjacent to 
intact peri-ulcer skin and the ipsilateral medial thigh (healthy sample) using a trephine 
before the initiation of therapy. After 4 weeks of sustained compression therapy, the ulcer 
biopsy was repeated. Following sample collection, the tissue was flash frozen. Samples were 
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kept at −80° C until homogenization was performed. Immunohistochemistry was not 
performed due to the limited biopsy size.
Protein Sample Preparation
Tissue was weighed and homogenized using a Tissue-Tearor (Biospec Products, Inc., 
Bartlesville, Oklahoma, United States of America) homogenizer in a buffer of Dulbecco’s-
Phosphate Buffered Saline (Sigma, St. Louis, Missouri, USA) and an EDTA-free protease 
inhibitor cocktail (Cat.# P8340 Sigma). 0.5 ml of buffer was added for each 30 mg of tissue 
sample. The homogenate was centrifuged (15,000g× 10 min. at 4° C), and the supernatant 
total protein concentration was determined using a bicinchoninic protein assay kit (Pierce, 
Rockford, Illinois, USA).19 Cytokine protein levels were normalized to total protein amount.
Protein Assays
Previous studies have validated the use of a multiplex assay for simultaneous measurement 
of multiple cytokines in various bodily fluids and cell culture.20–22 The preceding protein 
quantification methods were validated for use with tissue homogenate using both spike and 
recovery and dilution curve analysis by our group, and similar results have been 
published.23 Assays (n=30 ulcer tissue, n=23 healthy tissue) were performed in duplicate. 
Protein levels of 22 cytokines were determined simultaneously in a single sample using the 
Luminex xMAP system and a commercial assay kit (Millipore, Billerica, Massachusetts, 
USA). The manufacturer’s instructions were followed, and samples were diluted with the 
kit’s calibrator diluent to a total protein concentration of 250 g/ml. Samples were read by a 
Luminex 100 dual laser apparatus (Luminex Corp., Austin, Texas, USA) with StarStation 
v2.0 software (Applied Cytometry Systems, Sacramento, California, USA).
TGF-β1 protein levels were measured using ELISA kits per the manufacturer’s (R&D 
Systems, Minneapolis, Minnesota, USA) protocol, as TGF-β1 was not available as a part of 
the multiplexed panel. The ELISA requires a larger tissue sample volume compared to the 
multiplex analysis; thus, not all biopsies were studied due to tissue sample size limitations 
(n=10 ulcer tissue, n=7 healthy tissue). Results were read on a MicroQuant plate reader with 
KCJunior v1.41 software (both Biotek Instruments, Winooski, Vermont, USA).
Statistical Analysis
Statistical comparisons were made using SAS v9.1 (SAS Institute Inc., Cary, North 
Carolina, USA). Statistical significance was set at P < 0.05, and measurements are presented 
as means ± standard deviations. One way analysis of variance (ANOVA) for repeated 
measures was used to detect differences between healthy tissue and before therapy measures 
as well as between before and after therapy measures. These models take into account that 
multiple responses are coming from the same participant. Because Wilks' Lambda, Pillai's 
Trace, Hotelling-Lawley Trace, and Roy's Greatest Root were all in lock-step agreement 
throughout (due to two groups in the ANOVA), the F statistic is reported. Comparisons 
between cytokine values in rapid versus delayed healers were performed using both 
parametric and non parametric methods. Subjects were divided into these groups based on 
whether or not the ulcer surface area change was more or less than 40% at 4 weeks of 
treatment. Modified t-tests comparing the means of cytokine levels in these two groups were 
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performed. The modification was utilized because the comparisons were not made between 
two homogenous groups. To confirm significance, nonparametric tests were conducted 
using Wilcoxon’s rank sum test.
RESULTS
Patient Demographics
Thirty-three patients with 34 limbs affected with new untreated ulcers were enrolled in the 
study. Two were screen failures due to a lack of venous insufficiency on duplex studies and 
one was found to have an ABI < 0.7. One patient was unable to comply with compression 
treatment leaving 30 limb ulcers for analysis. Patient demographics and co-morbidities are 
listed in Table I. CEAP criteria for venous insufficiency etiology, anatomy and 
pathophysiology are provided in Table II. The average initial ulcer size was 21.5 ± 26.8 
cm2. After 4 weeks of treatment, 2 ulcers were completely healed, and 3 ulcers had enlarged. 
Half of the ulcers healed at least 40% with 4 weeks of treatment, and the average ulcer size 
decreased by 54%.
Cytokine protein levels
Twenty two cytokines were measured using a multiplex assay. Six of the 22 cytokines (IL-2, 
-5, -7, -12p70, -15, and -17) had either undetectable tissue measurements or no statistical 
significance when comparing healthy and ulcer tissue before and after compression therapy. 
The significant cytokines measured using the Luminex xMAP system and TGF-β1 are 
reported in Table III.
Cytokines in healthy tissue compared to ulcer tissue before compression
Table IV lists the cytokines demonstrating a significant difference between concentrations in 
healthy tissue compared to ulcer tissue prior to compression therapy. All of these proteins 
demonstrated significantly higher concentrations in ulcer tissue than in healthy tissue with 
the exception of IL-1α.
Cytokines in ulcer tissue before compression compared to after compression
Table V lists the cytokines demonstrating a significant difference between concentrations in 
ulcer tissue before compared to after 4 weeks of compression therapy. All of the listed 
proteins demonstrated significantly higher concentrations in ulcer tissue before compression 
therapy with the exception of TGF-β1 which increased significantly in ulcer tissue after 
compression for 4 weeks.
Association of cytokines and ulcer healing status
Cytokine levels in ulcer tissue were studied to determine whether they were able to predict 
rapid (40% or greater reduction in ulcer surface area) or delayed (less than 40% reduction in 
ulcer surface area) wound healing after 4 weeks of treatment. Table VI summarizes the 
findings. Prior to compression therapy, ulcers with higher levels of IL-1α, IL-1β, IFN-γ, 
IL-12p40 and GM-CSF were more likely to be rapid healers. After 4 weeks of compression, 
ulcers with higher levels of IL-1 Ra were more likely to be rapid healers. Total change in 
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IFN-γ levels was also predictive of healing. Protein levels before and after compression for 
the cytokines demonstrating significant associations with healing are illustrated in Figure 1. 
The relationship between TGF-β1 levels and ulcer healing could not be determined due to an 
insufficient number of measurements.
DISCUSSION
This study reports for the first time, to our know ledge, the relationships between cytokine 
protein levels before and after compression therapy in venous leg ulcers and healthy tissue. 
A multiplexed assay provided simultaneous measurements of cytokines in a single tissue 
homogenate sample.
Although the pathogenesis of venous insufficiency leading to ulceration is likely multi-
factorial, our results indicate that specific inflammatory mediators are associated with time- 
and pattern-dependent healing progression. It appears from our data that the presence of a 
robust pro-inflammatory environment is likely required in the early stages of wound repair. 
Several authors have argued that the initial inflammatory response to injury likely programs 
the end of inflammation through ‘pro-resolution signaling networks’, including lipid 
mediator classes.24, 25 Specific to wound healing, the importance of the initial inflammatory 
phase has been noted in several studies, as a paucity of pro-inflammatory cells in a newly 
created wound bed results in delayed healing.26–28 Hubner et al showed a strong and early 
induction of pro-inflammatory cytokines following cutaneous injury. This induction was 
significantly reduced in healing impaired glucocorticoid treated mice.29 Consistent with 
multiple other studies, our data also indicates that the quantity of pro-inflammatory 
cytokines is significantly diminished in the tissue of rapid healers. We believe that CVI ulcer 
delayed healers have wounds that cannot mount an appropriate initial inflammatory 
response; thus, the prolonged cellular effects of inflammation are not propagated.
In comparison to healthy tissue samples, inflammatory cytokines, in addition to TGF-β1, 
were significantly elevated in ulcer tissue before multilayer compression therapy. The 
exception was IL-1α, which had lower levels in untreated CVI ulcer tissue than in healthy 
tissue. IL-1 is a pleiotropic cytokine, and previous studies have reported that IL-1α is 
present in lower levels in acute wound fluid when compared to fluid from chronic wounds.30
In our study, treatment of CVI ulcers with 4 weeks of compression therapy resulted in a 
decrease in the levels of the majority of the pro-inflammatory ulcer cytokines. Trengove et 
al reported that the pro-inflammatory cytokines IL-1, IL-6 and TNF-α have significantly 
higher levels in the fluid of non-healing wounds. In their study, in vitro fibroblast 
proliferative response was stunted when this non-healing wound fluid was added to cultures; 
thus, healing may be impaired by specific inflammatory mediators.31
Several of the proteins studied in this project have known anti-inflammatory properties, 
including TGF-β1, IL-10 and IL-1 Ra. TGF-β1 levels in ulcer tissue were significantly 
increased after 4 weeks of sustained compression therapy. TGF-β1 has been reported to 
regulate dermal tissue fibrosis, although the addition of TGF-β1 to venous ulcer fibroblasts 
has not been shown to induce proliferation.32, 33 Likewise, the potent anti-inflammatory 
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cytokine IL-10 had higher levels following compression which approached statistical 
significance (P=0.076).
Rapidly healing wounds were associated with higher levels of pro-inflammatory cytokines 
in the ulcer tissue at initial presentation before compression treatment. Five pro-
inflammatory cytokines displayed this significant finding, including IL-1α, IL-1β, IFN-γ, 
IL-12p40 and GM-CSF. Elevated expression of these cytokines may indicate that a wound 
has mounted and maintained an appropriate level of defensive mechanisms and is prepared 
for future coordinated cellular repair. Our data indicates that although delayed healing CVI 
ulcers contain inflammatory proteins, these cytokines were present at significantly lower 
levels, perhaps due to increased cellular senescence.
Importantly, the rapid healing ulcers not only had very high pre-compression levels of IFN-γ 
but also had a significant reduction in this cytokine following compression therapy. IFN-γ is 
a glycoprotein with numerous immunological functions. IFN-γ has been shown to suppress 
numerous genes responsible for the cell cycle, DNA replication and RNA metabolism of 
keratinocytes; thus, it is thought to increase host defense against viruses by denying access 
into cells in which to replicate.34 Konur has shown that IFN-γ is the key mediator in 
keratinocyte apoptosis.35 IFN-γ is also a positive regulator for the production of TNF-α 
from keratinocytes, and it acts synergistically with IL-1α to produce TNF-α.36 
Administration of recombinant murine IFN-γ to mice with surgically created incisions 
caused significant impairment in wound healing.37 Likewise, multiple sclerosis patients 
receiving injections of interferon have experienced skin inflammation and skin 
breakdown.38, 39 Data suggests that IFN-γ expression is important during the inflammatory 
phase of acute wound healing.
We believe that up-regulation of pro-inflammatory cytokines at baseline may be a marker 
for healthier peri-wound tissue that has better potential to heal. However, it is similarly 
important for up-regulated cytokine levels to be controlled to allow resumption of healing. 
We agree with the hypothesis previously proposed by Simka that an anti-IFN-γ agent may 
have a significant clinical impact on the treatment of CVI ulceration, and anti-interferon 
therapy is already used to treat a variety of diseases.40
Rapid healers also expressed a significantly higher level of IL-1 Ra in ulcer tissue compared 
to delayed healers after compression therapy. This suggests that up-regulation of anti-
inflammatory cytokines is important during treatment to support the healing process. Mice 
homozygous for a null mutation in the gene encoding IL-1 Ra develop lethal arterial 
inflammation.41 An imbalance between IL-1 Ra and IL-1 also predisposes patients to 
inflammatory arthritis and arteritis forming the basis for the treatment of resistant cases of 
rheumatoid arthritis with IL-1 Ra (Anakinra; Amgen, Thousand Oaks, CA).42
This study has significant limitations that must be considered during interpretation of the 
data. With a study population of 30 limbs, subset analysis is not possible for patient 
demographics and risk factors and some relevant associations between cytokine levels and 
outcomes may be missed due to a lack of power. Also, when studying a panel of 22 
predictors it is possible that any positive finding may be related to chance. Therefore, we 
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believe that further studies in human tissue in this population and in populations with other 
types of non-healing ulcers are required to strengthen the associations outlined in this 
manuscript.
CONCLUSION
The results of this study indicate tha t CVI ulcers have high levels of inflammatory proteins 
prior to compression therapy. Importantly, rapidly healing ulcers likely need an elevated 
level of pro-inflammatory cytokines, including IL-1α, IL-1β, IFN-γ, IL-12p40 and GM-CSF 
within the ulcer bed before initiating compression therapy. Compression therapy is 
associated with a reduction in the pro-inflammatory ulcer environment, especially INF-γ, 
and promotes anti-inflammatory proteins. This data suggests that cytokines may provide 
targets in which inhibition or promotion at appropriate time points in the healing process 
may provide novel therapeutic approaches to CVI ulcer healing.
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Levels of cytokine in ulcer tissue before and after 4 weeks of compression therapy for ulcers 
that healed > 40% compared to ulcers that healed < 40% at 4 weeks. A: Interferon-gamma 
(IFN-γ), B: Interleukin-1α (IL–1α), C: Interleukin-1β (IL-1β), D: Interleukin-1 receptor 
antagonist (IL-1RA), E: Interleukin-12p40 (IL-12p40), F: Granulocyte macrophage colony 
stimulating factor (GM-CSF). All levels are expressed in picograms of cytokine per 
microgram of protein in the tissue biopsy sample. * = statistically significant with P < .05.
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Mean Age 57.9 ± 16.4 yrs
Females 20 68.9
Hypertension 9 31
ABI less than 0.9 1 3.4
History of DVT 17 58.6
Diabetes 7 24.1
Hypercoagulable State # 2 6.9
Cardiac Disease * 7 24.1
#
Per patient report/documentation. Not routinely measured by our group in CVI ulcer patients.
*
CHF, CAD, Atherosclerosis, MI, Dysrhythmia

















  Primary 8 27%
  Secondary 22 73%
Anatomy
  Deep venous reflux 12 40%
  Superficial venous reflux 4 13%
  Deep and superficial reflux 14 47%
Pathophysiology
  Reflux only 21 70%
  Reflux and obstruction 9 30%
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